Diabetes drug may shield breast cancer patients from uterine thickening

NCT ID NCT07145827

Completed Disease control Sponsor: Uruk University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looked at whether metformin, a common diabetes drug, can reduce the thickening of the uterine lining caused by tamoxifen in postmenopausal breast cancer survivors. Sixty women who had been taking tamoxifen for at least a year were given either metformin or a placebo for 12 months. Researchers measured their endometrial thickness with ultrasound at regular visits to see if metformin made a difference.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: metformin
What this could lead to: If it works, this could offer a way to manage a common side effect of tamoxifen, potentially reducing the risk of endometrial cancer in breast cancer survivors.
What could go wrong: This is a small, completed trial with only 60 participants. The results may not apply to all patients, and metformin can cause gastrointestinal side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm Endometrial Hyperplasia endometrium neoplasm estrogen-receptor positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER ENDOMETRIAL HYPERPLASIA AND ENDOMETRIAL CANCERS

Contacts and locations

Locations

Baghdad Medical City / Department of Oncology

Baghdad, Baghdad Governorate, 10045, Iraq

More trials for these conditions

Other studies related to the condition(s) this trial covers.